Developer docs
API playgroundTry for free, no card

Search company profiles

Control Bionics

Full company profile

uuid00031p3

Namestring
Control Bionics
Legal namestring
Control Bionics
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Control Bionics Limited (ASX: CBL) is a publicly listed neurotechnology company founded in 2006 and headquartered in Milford, Ohio (US operations) with its parent entity domiciled in Australia. The company develops and commercializes non-invasive AAC (augmentative and alternative communication) devices built on a proprietary neural-signal platform that captures surface electromyography (sEMG) bioelectric signals and 3D spatial movements, converting them into device control commands and speech-generating outputs for individuals with ALS/MND, cerebral palsy, spinal cord injury, traumatic brain injury, spinal muscular atrophy, and other neurodegenerative or complex physical conditions.

The core product portfolio centers on the NeuroNode wireless wearable sensor and its derivative speech-generating systems: NeuroNode Trilogy (multimodal: touch + eye gaze + EMG/spatial control, with up to 47% faster communication than eye gaze alone), NeuroNode Duo (touch + EMG), EyeGaze Duo (eye gaze only), UNO Touch (entry-level AAC device), and Cosmos Connect (portable multi-function controller). Supporting offerings include DROVE (autonomous wheelchair navigation), NeuroStrip (sports performance), the ChatCrackers AI storytelling application, and accessories including mounting systems. The platform integrates with leading AAC software (Grid 3, MindExpress, Avaz, Predictable), iOS and Windows operating systems, Apple-approved assistive technology frameworks, the Apple BCI HID protocol, and Tolt Technologies Ability Drive for wheelchair control.

Control Bionics generates revenue primarily through hardware sales of speech-generating devices ($3,200-$20,875 AUD per unit), supplemented by bundled one-time communication software licenses, rental and lease arrangements (3-month rental with buyout, 12-month lease), professional services including device setup and clinical support, and funding navigation services. The company operates across Australia, the United States, Canada, and other regions, distributing through NDIS-registered provider status in Australia, Medicare/Medicaid/private insurance channels in the US (with HCPCS Level II code E2513 effective October 2024), an exclusive US joint venture with NextLevel Assistive Technology, a pilot with Tobii Dynavox, a global distributor and partner portal network, and a Help Hope Live nonprofit fundraising referral partnership. The company holds FDA, TGA, and CE regulatory clearances and maintains HIPAA-compliant data practices.

Short descriptiontext

Control Bionics develops non-invasive, sEMG-based wearable AAC devices and speech-generating systems that restore communication for individuals with ALS, cerebral palsy, brain injury, and other conditions, serving thousands of users across Australia, the US, and Canada via hardware sales and insurance/NDIS funding channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
augmentative communication devices, speech generating devices, EMG wearable sensors, assistive communication technology, neural signal platform
Industry3 codes
PRIMARYEDAKAIAB
AAC (Augmentative & Alternative Communication) Devices, Apps & Training
Education/Special Education & Learning Support Services/Assistive Technology (AT) Assessment, Devices & Training
SECONDARYHDACAFAL
Assistive & Accessibility Input Devices (Switches, Adaptive Controllers, Braille Keyboards)
Hardware, Technology & Telecom/Computing Hardware & Peripherals/Input Devices & Accessories (Keyboards, Mice, Controllers)
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code4 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Computer Peripheral Equipment, Nec3577
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Assistive Communication Devices (AAC)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AAC Device and Hardware Sales
TypeHardware Sales
Description

Sale of speech-generating devices and neural-signal hardware including NeuroNode Trilogy, NeuroNode Duo, EyeGaze Duo, NeuroNode sensor, UNO Touch, Cosmos Connect, and accessories. Devices are available for purchase, rental (3 or 6 months with buyout option), or 12-month lease (NeuroNode Trilogy). Hardware sales are the primary revenue driver.

controlbionics.com
2Communication Software Licenses
TypeOne Time License
Description

Full communication software licenses (e.g., Grid 3) are bundled with device purchases. Software provides symbol-based, text-based, phrase/sentence, and letter/word communication tools.

controlbionics.com
3Professional Services and Clinical Support
TypeProfessional Services
Description

Charges for device installation and setup by product specialists, ongoing clinical support, training for users and caregivers, and AAC funding advocacy services. NDIS report preparation support and insurance funding navigation are provided through internal dedicated funding teams.

controlbionics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details8 tiers
1NeuroNode Trilogy System — 3-month rental with buyout option
ModelHybridBilling cadenceMulti-year contract
Notes

Starting from $8,000 AUD for 3-month rental with buyout option. Purchase price deducted from final amount if device is purchased.

controlbionics.com
2NeuroNode Trilogy System — Purchase
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Starting from $20,875 AUD. Includes full communication software license, all NeuroNode Trilogy components (Windows tablet, protective case, eye gaze camera, NeuroNode device, electrodes, bands, and accessories).

controlbionics.com
3NeuroNode Trilogy System — 12-month Lease
ModelSubscriptionBilling cadenceMulti-year contract
Notes

$9,900 AUD for 12-month lease. Includes full warranty and product specialist setup. Buyout option not available at end of lease.

controlbionics.com
4NeuroNode Duo — 3-month rental with buyout option
ModelHybridBilling cadenceMulti-year contract
Notes

Starting from $5,400 AUD for 3-month rental with buyout option. Purchase starting from $16,875 AUD.

controlbionics.com
5NeuroNode Duo — Purchase
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Starting from $16,875 AUD. Available in Windows and iOS (10.9" or 12.9" iPad) configurations.

controlbionics.com
6EyeGaze Duo — 3-month rental with buyout option
ModelHybridBilling cadenceMulti-year contract
Notes

Starting from $3,800 AUD for 3-month rental with buyout option. Purchase starting from $9,000 AUD.

controlbionics.com
7UNO Touch — 3-month rental with buyout option
ModelHybridBilling cadenceMulti-year contract
Notes

Starting from $1,100 AUD for 3-month rental with buyout option. Purchase starting from $3,200 AUD. Available in Windows and iOS versions.

controlbionics.com
8NeuroNode (standalone sensor) — US HCPCS billing
ModelOtherBilling cadencePay-as-you-go
Notes

NeuroNode is billed as a speech generating device accessory under HCPCS Level II code E2513 (E2513: Accessory for speech generating device, electromyographic sensor). Previously coded under E2599. Recognized by CMS under Durable Medical Equipment (DME) benefit, enabling direct billing from October 2024.

controlbionics.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1NeuroNode
Description

Wireless, wearable sensor that allows users to control devices using bioelectric signals or spatial movements for assistive communication

controlbionics.com
+9 more records
Core offering1 text field

Control Bionics develops and sells a portfolio of non-invasive, EMG-based speech-generating devices (AAC systems) that convert bioelectric muscle signals, eye movements, or touch into speech and device control for individuals who have lost the ability to speak or have complex physical access needs. Core products include the NeuroNode wireless wearable sensor, the NeuroNode Trilogy multimodal speech-generating system, NeuroNode Duo, EyeGaze Duo, UNO Touch, Cosmos Connect, and the DROVE autonomous wheelchair module, sold with full communication software, accessories, and clinical support services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 47% faster communication compared to traditional eye gaze alone through multimodal sensing on the NeuroNode Trilogy
+3 more records
Product overview1 text field

Control Bionics delivers a portfolio of neurotechnology products centered on its proprietary Neural-Signal Platform, which captures physiological EMG (electromyography) data non-invasively and converts it into actionable device control and communication outcomes. The core product line is the NeuroNode ecosystem of AAC (augmentative and alternative communication) speech-generating devices: the NeuroNode wireless wearable EMG sensor serves as the foundational access technology, which powers the NeuroNode Trilogy System (multimodal: touch + eye gaze + EMG), NeuroNode Duo (touch + EMG), EyeGaze Duo (eye gaze only), and UNO Touch (accessibility-focused speech-generating device) — all available in Windows and iOS configurations. Supporting products include Cosmos Connect (portable multi-function controller), DROVE (autonomous wheelchair navigation), NeuroStrip (sports performance), and the AI-powered ChatCrackers storytelling application. The portfolio spans assistive communication (for ALS, cerebral palsy, SCI, TBI), rehabilitation, sports performance, and research applications, with regulatory clearance in the US (FDA), Australia (TGA), and Europe (CE).

Product and service11 records
1NeuroNode
CategoryAssistive Communication Devices
Description

The NeuroNode is a wireless, wearable sensor that uses bioelectric EMG signals or 3D spatial awareness to give users control over technology. It interprets the smallest muscle signals, allowing individuals with limited motor control to access computers, phones, tablets, and AAC devices. Attaches non-invasively with adhesive or non-adhesive electrode and NeuroNode band.

2NeuroNode Trilogy System
CategoryAssistive Communication Devices
Description

A multimodal speech-generating device combining touch control, eye gaze control, and NeuroNode EMG/spatial sensing in a single system. Available in Windows and iOS configurations. Provides three access methods for faster and less fatiguing communication for individuals with ALS, cerebral palsy, spinal cord injury, and brain injury.

3NeuroNode Duo
CategoryAssistive Communication Devices
Description

A speech-generating device combining touch control and NeuroNode EMG sensor, providing flexible dual-mode access. Available in Windows and iOS (10.9-inch or 12.9-inch iPad) configurations, it offers expanded communication possibilities for users who benefit from muscle-signal-based switching alongside touch input.

4EyeGaze Duo
CategoryAssistive Communication Devices
Description

An eye gaze-based speech-generating device allowing users to control devices using their eyes. Users can upgrade to the NeuroNode Trilogy by adding a NeuroNode sensor for combined eye gaze and EMG access.

5UNO Touch
CategoryAssistive Communication Devices
Description

A lightweight, rugged speech-generating device for people with communication disabilities, available in Windows and iOS versions. Features a detachable external wireless speaker, 8-hour battery life (speaker: 15 hours), and compatibility with multiple communication software programs.

6Cosmos Connect
CategoryAssistive Communication Devices
Description

A small, portable device enabling users to play video games, activate switches, drive independently, and check text messages using a single NeuroNode. Serves as the platform for the ChatCrackers AI application.

7DROVE Autonomous Wheelchair Module
CategoryAssistive Mobility Technology
Description

The world's first autonomous driving wheelchair module. Allows users to independently navigate their home environment by selecting pre-defined destinations on their AAC device, removing the need to manually steer through tight corridors and doorways. Supports multiple access methods including AAC selection.

8NeuroStrip
CategorySports Performance Technology
Description

A neural-signal capture device for sports performance applications, providing muscle-level bioelectric insights to optimize athletic performance and recovery. Showcased at PEAK 2026 conference.

9ChatCrackers AI Application
CategoryAI Communication Application
Description

An AI-powered application built on the Cosmos Connect platform. Provides storytelling and picture-creation activities for AAC users using switch access (including NeuroNode) in an errorless, engaging way. The AI generates custom images and narratives based on user selections, enabling creative self-expression for individuals with complex physical needs.

10Oskol 2 Eye Gaze Device
CategoryAssistive Communication Devices
Description

A speech-generating device designed exclusively for the 13-inch iPad Air, powered by Hiru, the world's first multiplatform eye-tracker. Part of the next-generation eye gaze communication product line.

11Funding Navigation Services
CategoryProfessional Services
Description

Internal funding team guides users and professionals through Medicare, Medicaid, NDIS, and private insurance processes for obtaining AAC device funding. Includes assistance with assistive technology reports, NDIS plan navigation, and ALS Association grant applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1NextLevel Assistive Technology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

Exclusive US joint venture for manufacturing and distributing iOS-based speech-generating devices. The JV targets the growing US AAC market and aims to sell between 1,000 and 1,500 devices annually within a market valued at USD 100–150 million. The company continues efforts to expand its US presence through this strategic partnership despite current financial challenges.

tradingview.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-11
Description

Control Bionics adopted Apple's Brain-Computer Interface Human Interface Device (BCI HID) protocol across its NeuroNode and NeuroNode Trilogy product lines for iOS-based AAC tools. The integration reduces setup complexity, improves neural signal feedback, and enables automatic Switch Control activation on iOS devices. Beta released to existing customers.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-04-17
Description

Help Hope Live is a nonprofit that partners with Control Bionics clients to start community-based medical fundraising campaigns for unmet medical expenses including AAC devices. Donations are tax-deductible, verified for medical diagnosis, and administered by Help Hope Live, meaning funds typically won't count against client asset-based benefits.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-06
Description

NeuroNode was listed as a third-party assistive technology device on Apple's official website, making it part of Apple's Apple-approved assistive technologies. This listing provides users and clinicians confidence that NeuroNode meets Apple's standards for assistive technology integration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading AAC and eye-gaze communication device vendor, part of Tobii AB. Directly comparable as a speech-generating device supplier serving the same ALS, CP, and pediatric AAC end markets, and currently a pilot channel partner for NeuroNode sEMG technology in the US.

TypeDirect peer
Description

Leading US-based AAC device manufacturer offering the ChatPlus, TouchChat, and WordPower app ecosystem across iOS-based speech-generating devices. Directly competes in the same AAC funding and clinical workflow that Control Bionics targets through its NextLevel JV.

TypeBroad incumbent
Description

Established manufacturer of mounting systems for AAC devices, eye-gaze cameras, and assistive technology peripherals. Comparable as an ecosystem enabler whose VESA mounting hardware Control Bionics sells alongside its eye-gaze products.

TypeRegional player
Description

Australian AAC and assistive technology distributor and reseller with deep NDIS and Australia-specific clinical relationships. Comparable as an Australia-headquartered AAC peer and a regional channel overlap with Control Bionics' home market.

TypeDirect peer
Description

US AAC device and apps manufacturer focused on aphasia and adult speech-generating needs. Competes in the same Medicare/Medicaid-funded AAC segment with its TalkPath Therapy and dedicated speech-generating tablets.

TypeEmerging player
Description

UK-based assistive and AAC technology vendor offering eye-gaze devices and communication apps for special-needs education. Comparable as a fellow niche AAC vendor targeting schools and special-education settings similar to Control Bionics' education segment.

TypeBroad incumbent
Description

US assistive technology manufacturer of switches, AAC devices, and environmental controls. Comparable as a broad AAC and switch-access incumbent whose single-switch scanning ecosystem overlaps with NeuroNode's switch-control positioning.

8Smartbox Assistive Technology
TypeDirect peer
Description

UK-based AAC vendor behind the Grid 3 communication software, which Control Bionics bundles with NeuroNode devices. A direct peer through Grid 3's installed base and complementary AAC hardware (e.g., Grid Pad).

TypeEmerging player
Description

US-based AAC app and speech-generating device developer (e.g., Forbes AAC apps on iPad) competing in the same lightweight, iOS-centric AAC category that Control Bionics addresses through its NextLevel JV and Oskol 2 devices.

TypeDirect peer
Description

Maker of the Ability Drive powered-wheelchair control system, which integrates with NeuroNode Trilogy for eye-gaze-based wheelchair driving. Overlaps in the AAC-plus-powered-mobility niche and shares the same end-user population.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Control Bionics

Assistive Communication Devices (AAC)controlbionics.com

Control Bionics develops non-invasive, sEMG-based wearable AAC devices and speech-generating systems that restore communication for individuals with ALS, cerebral palsy, brain injury, and other conditions, serving thousands of users across Australia, the US, and Canada via hardware sales and insurance/NDIS funding channels.

What Control Bionics does

Control Bionics Limited (ASX: CBL) is a publicly listed neurotechnology company founded in 2006 and headquartered in Milford, Ohio (US operations) with its parent entity domiciled in Australia. The company develops and commercializes non-invasive AAC (augmentative and alternative communication) devices built on a proprietary neural-signal platform that captures surface electromyography (sEMG) bioelectric signals and 3D spatial movements, converting them into device control commands and speech-generating outputs for individuals with ALS/MND, cerebral palsy, spinal cord injury, traumatic brain injury, spinal muscular atrophy, and other neurodegenerative or complex physical conditions.

The core product portfolio centers on the NeuroNode wireless wearable sensor and its derivative speech-generating systems: NeuroNode Trilogy (multimodal: touch + eye gaze + EMG/spatial control, with up to 47% faster communication than eye gaze alone), NeuroNode Duo (touch + EMG), EyeGaze Duo (eye gaze only), UNO Touch (entry-level AAC device), and Cosmos Connect (portable multi-function controller). Supporting offerings include DROVE (autonomous wheelchair navigation), NeuroStrip (sports performance), the ChatCrackers AI storytelling application, and accessories including mounting systems. The platform integrates with leading AAC software (Grid 3, MindExpress, Avaz, Predictable), iOS and Windows operating systems, Apple-approved assistive technology frameworks, the Apple BCI HID protocol, and Tolt Technologies Ability Drive for wheelchair control.

Control Bionics generates revenue primarily through hardware sales of speech-generating devices ($3,200-$20,875 AUD per unit), supplemented by bundled one-time communication software licenses, rental and lease arrangements (3-month rental with buyout, 12-month lease), professional services including device setup and clinical support, and funding navigation services. The company operates across Australia, the United States, Canada, and other regions, distributing through NDIS-registered provider status in Australia, Medicare/Medicaid/private insurance channels in the US (with HCPCS Level II code E2513 effective October 2024), an exclusive US joint venture with NextLevel Assistive Technology, a pilot with Tobii Dynavox, a global distributor and partner portal network, and a Help Hope Live nonprofit fundraising referral partnership. The company holds FDA, TGA, and CE regulatory clearances and maintains HIPAA-compliant data practices.

Control Bionics firmographics

Firmographics
Name
Control Bionics
Legal name
Control Bionics
Website
https://controlbionics.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Control Bionics develops non-invasive, sEMG-based wearable AAC devices and speech-generating systems that restore communication for individuals with ALS, cerebral palsy, brain injury, and other conditions, serving thousands of users across Australia, the US, and Canada via hardware sales and insurance/NDIS funding channels.
Ownership category
akta.pro rank

Control Bionics industry classification

Industry
Product category
Assistive Communication Devices (AAC)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Computer Peripheral Equipment, Nec (3577), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYEDAKAIAB
AAC (Augmentative & Alternative Communication) Devices, Apps & Training
Education/Special Education & Learning Support Services/Assistive Technology (AT) Assessment, Devices & Training
SECONDARYHDACAFAL
Assistive & Accessibility Input Devices (Switches, Adaptive Controllers, Braille Keyboards)
Hardware, Technology & Telecom/Computing Hardware & Peripherals/Input Devices & Accessories (Keyboards, Mice, Controllers)
SECONDARYHLAHAMAG
Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)

Keywords

  • Augmentative communication devices
  • Speech generating devices
  • EMG wearable sensors
  • Assistive communication technology
  • Neural signal platform

Where Control Bionics is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Control Bionics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. AAC Device and Hardware Sales: Sale of speech-generating devices and neural-signal hardware including NeuroNode Trilogy, NeuroNode Duo, EyeGaze Duo, NeuroNode sensor, UNO Touch, Cosmos Connect, and accessories. Devices are available for purchase, rental (3 or 6 months with buyout option), or 12-month lease (NeuroNode Trilogy). Hardware sales are the primary revenue driver.
  2. Communication Software Licenses: Full communication software licenses (e.g., Grid 3) are bundled with device purchases. Software provides symbol-based, text-based, phrase/sentence, and letter/word communication tools.
  3. Professional Services and Clinical Support: Charges for device installation and setup by product specialists, ongoing clinical support, training for users and caregivers, and AAC funding advocacy services. NDIS report preparation support and insurance funding navigation are provided through internal dedicated funding teams.

Pricing tiers

ModelBillingPrice
HybridMulti-year contractNeuroNode Trilogy System — 3-month rental with buyout option
One time/ perpetual licensePay-as-you-goNeuroNode Trilogy System — Purchase
SubscriptionMulti-year contractNeuroNode Trilogy System — 12-month Lease
HybridMulti-year contractNeuroNode Duo — 3-month rental with buyout option
One time/ perpetual licensePay-as-you-goNeuroNode Duo — Purchase
HybridMulti-year contractEyeGaze Duo — 3-month rental with buyout option
HybridMulti-year contractUNO Touch — 3-month rental with buyout option
OtherPay-as-you-goNeuroNode (standalone sensor) — US HCPCS billing

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Control Bionics product offering

Product offering

Core offering

Control Bionics develops and sells a portfolio of non-invasive, EMG-based speech-generating devices (AAC systems) that convert bioelectric muscle signals, eye movements, or touch into speech and device control for individuals who have lost the ability to speak or have complex physical access needs. Core products include the NeuroNode wireless wearable sensor, the NeuroNode Trilogy multimodal speech-generating system, NeuroNode Duo, EyeGaze Duo, UNO Touch, Cosmos Connect, and the DROVE autonomous wheelchair module, sold with full communication software, accessories, and clinical support services.

Product overview

Control Bionics delivers a portfolio of neurotechnology products centered on its proprietary Neural-Signal Platform, which captures physiological EMG (electromyography) data non-invasively and converts it into actionable device control and communication outcomes. The core product line is the NeuroNode ecosystem of AAC (augmentative and alternative communication) speech-generating devices: the NeuroNode wireless wearable EMG sensor serves as the foundational access technology, which powers the NeuroNode Trilogy System (multimodal: touch + eye gaze + EMG), NeuroNode Duo (touch + EMG), EyeGaze Duo (eye gaze only), and UNO Touch (accessibility-focused speech-generating device) — all available in Windows and iOS configurations. Supporting products include Cosmos Connect (portable multi-function controller), DROVE (autonomous wheelchair navigation), NeuroStrip (sports performance), and the AI-powered ChatCrackers storytelling application. The portfolio spans assistive communication (for ALS, cerebral palsy, SCI, TBI), rehabilitation, sports performance, and research applications, with regulatory clearance in the US (FDA), Australia (TGA), and Europe (CE).

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroNode: Wireless, wearable sensor that allows users to control devices using bioelectric signals or spatial movements for assistive communication
  • NeuroNode Trilogy
  • NeuroNode Duo
  • EyeGaze Duo
  • UNO Touch
  • NeuroStrip
  • Cosmos Connect
  • Oskol 2
  • DROVE
  • The Block

Products and services

  • NeuroNode The NeuroNode is a wireless, wearable sensor that uses bioelectric EMG signals or 3D spatial awareness to give users control over technology. It interprets the smallest muscle signals, allowing individuals with limited motor control to access computers, phones, tablets, and AAC devices. Attaches non-invasively with adhesive or non-adhesive electrode and NeuroNode band.
  • NeuroNode Trilogy System A multimodal speech-generating device combining touch control, eye gaze control, and NeuroNode EMG/spatial sensing in a single system. Available in Windows and iOS configurations. Provides three access methods for faster and less fatiguing communication for individuals with ALS, cerebral palsy, spinal cord injury, and brain injury.
  • NeuroNode Duo A speech-generating device combining touch control and NeuroNode EMG sensor, providing flexible dual-mode access. Available in Windows and iOS (10.9-inch or 12.9-inch iPad) configurations, it offers expanded communication possibilities for users who benefit from muscle-signal-based switching alongside touch input.
  • EyeGaze Duo An eye gaze-based speech-generating device allowing users to control devices using their eyes. Users can upgrade to the NeuroNode Trilogy by adding a NeuroNode sensor for combined eye gaze and EMG access.
  • UNO Touch A lightweight, rugged speech-generating device for people with communication disabilities, available in Windows and iOS versions. Features a detachable external wireless speaker, 8-hour battery life (speaker: 15 hours), and compatibility with multiple communication software programs.
  • Cosmos Connect A small, portable device enabling users to play video games, activate switches, drive independently, and check text messages using a single NeuroNode. Serves as the platform for the ChatCrackers AI application.
  • DROVE Autonomous Wheelchair Module The world's first autonomous driving wheelchair module. Allows users to independently navigate their home environment by selecting pre-defined destinations on their AAC device, removing the need to manually steer through tight corridors and doorways. Supports multiple access methods including AAC selection.
  • NeuroStrip A neural-signal capture device for sports performance applications, providing muscle-level bioelectric insights to optimize athletic performance and recovery. Showcased at PEAK 2026 conference.
  • ChatCrackers AI Application An AI-powered application built on the Cosmos Connect platform. Provides storytelling and picture-creation activities for AAC users using switch access (including NeuroNode) in an errorless, engaging way. The AI generates custom images and narratives based on user selections, enabling creative self-expression for individuals with complex physical needs.
  • Oskol 2 Eye Gaze Device A speech-generating device designed exclusively for the 13-inch iPad Air, powered by Hiru, the world's first multiplatform eye-tracker. Part of the next-generation eye gaze communication product line.
  • Funding Navigation Services Internal funding team guides users and professionals through Medicare, Medicaid, NDIS, and private insurance processes for obtaining AAC device funding. Includes assistance with assistive technology reports, NDIS plan navigation, and ALS Association grant applications.

Quantifiable outcome

  • Up to 47% faster communication compared to traditional eye gaze alone through multimodal sensing on the NeuroNode Trilogy
  • +3 more outcomes

Companies that use Control Bionics

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Control Bionics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability3 records

Feature7 records

Control Bionics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • NextLevel Assistive TechnologycoreStrategic or Co-development Partner · 25 February 2026Exclusive US joint venture for manufacturing and distributing iOS-based speech-generating devices. The JV targets the growing US AAC market and aims to sell between 1,000 and 1,500 devices annually within a market valued at USD 100–150 million. The company continues efforts to expand its US presence through this strategic partnership despite current financial challenges.
  • ApplecoreTechnology or Integration · 11 November 2025Control Bionics adopted Apple's Brain-Computer Interface Human Interface Device (BCI HID) protocol across its NeuroNode and NeuroNode Trilogy product lines for iOS-based AAC tools. The integration reduces setup complexity, improves neural signal feedback, and enables automatic Switch Control activation on iOS devices. Beta released to existing customers.
  • Help Hope LiveminorGTM or Marketing Partner · 17 April 2025Help Hope Live is a nonprofit that partners with Control Bionics clients to start community-based medical fundraising campaigns for unmet medical expenses including AAC devices. Donations are tax-deductible, verified for medical diagnosis, and administered by Help Hope Live, meaning funds typically won't count against client asset-based benefits.
  • Apple (as listed assistive technology partner)coreTechnology or Integration · 6 March 2025NeuroNode was listed as a third-party assistive technology device on Apple's official website, making it part of Apple's Apple-approved assistive technologies. This listing provides users and clinicians confidence that NeuroNode meets Apple's standards for assistive technology integration.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Control Bionics competitors and assessment

Company assessment

Direct peers

  • Tobii Dynavox: Market-leading AAC and eye-gaze communication device vendor, part of Tobii AB. Directly comparable as a speech-generating device supplier serving the same ALS, CP, and pediatric AAC end markets, and currently a pilot channel partner for NeuroNode sEMG technology in the US.
  • PRC-Saltillo: Leading US-based AAC device manufacturer offering the ChatPlus, TouchChat, and WordPower app ecosystem across iOS-based speech-generating devices. Directly competes in the same AAC funding and clinical workflow that Control Bionics targets through its NextLevel JV.
  • Lingraphica: US AAC device and apps manufacturer focused on aphasia and adult speech-generating needs. Competes in the same Medicare/Medicaid-funded AAC segment with its TalkPath Therapy and dedicated speech-generating tablets.
  • Smartbox Assistive Technology: UK-based AAC vendor behind the Grid 3 communication software, which Control Bionics bundles with NeuroNode devices. A direct peer through Grid 3's installed base and complementary AAC hardware (e.g., Grid Pad).
  • Tolt Technologies: Maker of the Ability Drive powered-wheelchair control system, which integrates with NeuroNode Trilogy for eye-gaze-based wheelchair driving. Overlaps in the AAC-plus-powered-mobility niche and shares the same end-user population.

Broad incumbents

  • Rehadapt: Established manufacturer of mounting systems for AAC devices, eye-gaze cameras, and assistive technology peripherals. Comparable as an ecosystem enabler whose VESA mounting hardware Control Bionics sells alongside its eye-gaze products.
  • Ablenet: US assistive technology manufacturer of switches, AAC devices, and environmental controls. Comparable as a broad AAC and switch-access incumbent whose single-switch scanning ecosystem overlaps with NeuroNode's switch-control positioning.

Regional players

  • Zyteq: Australian AAC and assistive technology distributor and reseller with deep NDIS and Australia-specific clinical relationships. Comparable as an Australia-headquartered AAC peer and a regional channel overlap with Control Bionics' home market.

Emerging players

  • Inclusive Technology: UK-based assistive and AAC technology vendor offering eye-gaze devices and communication apps for special-needs education. Comparable as a fellow niche AAC vendor targeting schools and special-education settings similar to Control Bionics' education segment.
  • Forbes AAC: US-based AAC app and speech-generating device developer (e.g., Forbes AAC apps on iPad) competing in the same lightweight, iOS-centric AAC category that Control Bionics addresses through its NextLevel JV and Oskol 2 devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Control Bionics social profiles

Digital presence

Control Bionics compliance and trust

Trust signal

Compliance6 records

Control Bionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Control Bionics leadership team

Management profile

Number of profiles

Profiles5 records

Control Bionics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Control Bionics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Control Bionics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Control Bionics

What does Control Bionics do?

Control Bionics develops and sells a portfolio of non-invasive, EMG-based speech-generating devices (AAC systems) that convert bioelectric muscle signals, eye movements, or touch into speech and device control for individuals who have lost the ability to speak or have complex physical access needs. Core products include the NeuroNode wireless wearable sensor, the NeuroNode Trilogy multimodal speech-generating system, NeuroNode Duo, EyeGaze Duo, UNO Touch, Cosmos Connect, and the DROVE autonomous wheelchair module, sold with full communication software, accessories, and clinical support services.

Is Control Bionics a public or private company?

Control Bionics is a public company. It is classified as public and is currently operating.

When was Control Bionics founded?

Control Bionics was founded in 2006. It employs 11 to 50 people.

Where is Control Bionics based?

Control Bionics is headquartered in Melbourne, Australia, in the Oceania region.

How does Control Bionics make money?

Three revenue lines are on record. AAC Device and Hardware Sales are the primary driver. The others are communication Software Licenses and professional Services and Clinical Support.

Who are Control Bionics's main competitors?

Direct peers on record are Tobii Dynavox, PRC-Saltillo, Lingraphica, Smartbox Assistive Technology and Tolt Technologies. Broad incumbents are Rehadapt and Ablenet. Zyteq is listed as a regional player. Emerging players are Inclusive Technology and Forbes AAC.

Does Control Bionics have an API?

No public API is recorded for Control Bionics.

What industry is Control Bionics in?

Control Bionics's product category is Assistive Communication Devices (AAC). Its primary akta.pro industry code is EDAKAIAB, AAC (Augmentative & Alternative Communication) Devices, Apps & Training, with a secondary code of HDACAFAL, Assistive & Accessibility Input Devices (Switches, Adaptive Controllers, Braille Keyboards). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewControl Bionics Secures FDA Registration for NeuroStrip Wearable PlatformControl Bionics has registered its NeuroStrip wearable platform with the US Food and Drug Administration as a medical device. This FDA registration is intended to enhance NeuroStrip's market presence in clinical rehabilitation, research, and human-computer interface applications, while also positioning the device favorably for discussions with existing and prospective clients. The company has also submitted applications for regulatory approval in Australia, Europe, and the UK to further support its growth strategy.KalkineControl Bionics (ASX:CBL) Advances Global Regulatory Strategy With NeuroStrip FDA ListingControl Bionics completed the US FDA registration and device listing for its NeuroStrip surface EMG wearable platform, formally establishing its presence within the US medical device regulatory framework. The FDA listing number is D605008, while the registration number is 3006789226, and the company anticipates that this credential will enhance its discussions with clinical providers and advance its commercialization efforts. Control Bionics is also pursuing regulatory registrations in Australia, Europe, and the UK as part of a broader global strategy.TipranksControl Bionics accelerates global rollout of assistive and neurotechnology platformControl Bionics Ltd. is advancing its assistive and neurotechnology platform with a focus on products like the NextLevel tablets, NeuroNode, and NeuroStrip. The company is implementing a distributor-led strategy to enhance market presence across several countries, and initial revenue from the NextLevel tablets suggests promising growth ahead. The expansion into key markets such as the U.K., Germany, and Japan is expected to further bolster international operations and revenue diversification.AInvestControl Bionics pause in trading :CBL AUControl Bionics Limited (ASX:CBL), a biotechnology company with a market capitalization of approximately $35.84 million, has experienced a trading halt on the Australian Securities Exchange with no specific reason disclosed at this time. Standard trading halt protocols are typically implemented to ensure market integrity and allow for the orderly dissemination of relevant information to investors. The resumption of trading will depend on the nature of the halt and the resolution of the underlying issue.ProactiveinvestorsInside Biotech: Neurotech moves from research labs to real-world healthcareControl Bionics Ltd reported commercial progress across its assistive communication, rehabilitation and sports performance businesses, with US states representing nearly 70% of the US population now funding its NeuroNode device through the E2513 HCPCS reimbursement pathway. The company has commenced funded sales through distribution agreements with Tobii Dynavox and PRC-Saltillo, and secured HMV insurance coverage in Germany, signalling a shift toward scaling distribution over new technology development. Control Bionics is also testing its NeuroStrip wearable platform with sports organizations including AFL, NRL and the Australian Institute of Sport, and plans to integrate with Apple's Brain-Computer Interface protocol in Q3 2026.Biotech DispatchNeurotechnology leader Nicholas Opie joins Control Bionics boardControl Bionics has appointed Professor Nicholas Opie as a Non-Executive Director and strategic advisor to strengthen its technical and commercial capabilities in neurotechnology. The appointment comes alongside the planned retirement of director Dr Stephanie Phillips and includes an agreement for Opie to receive 1.25 million options upon shareholder approval. Control Bionics continues to advance its NeuroNode and NeuroStrip platforms for global markets in assistive communication, rehabilitation, and sports performance.The Globe and MailControl Bionics Director Stephen Rix Increases Shareholding via On-Market PurchaseControl Bionics director Stephen Rix increased his stake in the company by purchasing 587,632 shares valued at $34,828 on 27 February 2026, raising his total holding to 6,321,847 shares. The purchase was made through Windward Capital Pty Limited outside any closed trading period with no disposals or changes to director-related contracts. The transaction is being characterized as a vote of confidence from a board member, which may positively influence investor sentiment toward the medtech company focused on assistive communication systems.TipranksControl Bionics Director Stephen Rix Increases Shareholding via On-Market PurchaseControl Bionics director Stephen Rix purchased 587,632 ordinary shares on February 27, 2026, through Windward Capital Pty Limited, valued at $34,828, increasing his total holding to 6,321,847 shares. The on-market purchase, executed outside any closed trading period, represents a direct financial commitment by a board member to the company. Market observers typically view such insider share purchases as a positive signal of management confidence in the company's future prospects within the medtech sector.TradingViewControl Bionics Signs US JV for iOS Speech Devices with NextLevel Assistive TechnologyControl Bionics entered an exclusive US joint venture with NextLevel Assistive Technology for manufacturing and distributing iOS-based speech-generating devices, focusing on the growing US AAC market. The joint venture aims to sell between 1,000 and 1,500 devices annually within a market valued at USD 100–150 million. The company continues efforts to expand its US presence through strategic partnerships, despite current financial challenges.